The role of physicochemical properties of entacapone and tolcapone on their efficacy during local intrastriatal administration

European Journal of Pharmaceutical Sciences

Volumn 24, Issue 5, 2005, Pages 503-511

  Forsberg, Markus M ^a   Huotari, Marko ^a   Savolainen, Jouko ^a   Männistö, Pekka T ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Apparent partition coefficient; Aqueous solubility; Catechol O methyltransferase; Entacapone; Microdialysis; Tolcapone

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; ENTACAPONE; HOMOVANILLIC ACID; TOLCAPONE;

AQUEOUS SOLUTION; ARTICLE; CONCENTRATION (PARAMETERS); CORPUS STRIATUM; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENCY; DRUG SOLUBILITY; ENZYME INHIBITION; LIPOPHILICITY; MALE; MICRODIALYSIS; NONHUMAN; PARTITION COEFFICIENT; PH; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT;

EID: 15244360472     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2005.01.005     Document Type: Article

References (40)

1. N.J. Abbott Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology Neurochem. Int. 45 2004 545 552
2. E. Acquas, E. Carboni, R.H.A. de Ree, M. Da Prada, and G. Di Chiara Extracellular concentrations of dopamine and metabolites in the rat caudate after oral administration of a novel catechol-O-methyltransferase inhibitor Ro 40-7592 J. Neurochem. 59 1992 326 330
3. U. Bickel Targeting macromolecules to the central nervous system D.J. Begley M.W. Bradbury J. Kreuter The Blood-Brain Barrier and Drug Delivery to the CNS 2000 Marcel Dekker New York 171 204
4. M.W. Bradbury Transport across the blood-brain barrier E.A. Neuwelt Implications of the Blood-Brain Barrier and Its Manipulation 1989 Plenum Publishing Corporation New York 119 136
5. R.A. Copeland Enzymes: A Practical Introduction to Structure, Mechanism, and Data analysis second ed. 2000 Wiley New York pp. 305-317
6. H. Davson, and M.B. Segal Physiology of the CSF and Blood-Brain Barriers 1996 CRC Press Boca Raton
7. E.C.M. de Lange, M.R. Bouw, J.W. Mandema, M. Danhof, A.G. de Boer, and D.D. Breimer Application of intracerebral microdialysis to study regional distribution kinetics of drugs in rat brain Br. J. Pharmacol. 116 1995 2538 2544
8. C. DeSanti, P.C. Giulianotti, A. Pietrabissa, F. Mosca, and G.M. Pacifici Catechol-O-methyltransferase: variation in enzyme activity and inhibition by entacapone and tolcapone Eur. J. Clin. Pharmacol. 54 1998 215 219
9. J. Dingemanse Issues important for rational COMT inhibition Neurology 55 Suppl. 4 2000 S24 S27
10. J. Dingemanse Catechol-O-methyltransferase inhibitors: clinical potential in the treatment of Parkinson's disease Drug Dev. Res. 42 1997 1 25
11. J. Dingemanse, K.M. Jorga, M. Schmitt, R. Gieschke, B. Fotteler, G. Zürcher, M. Da Prada, and P. van Brummelen Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans Clin. Pharmacol. Ther. 57 1995 508 517
12. M. Forsberg, M. Lehtonen, M. Heikkinen, J. Savolainen, T. Jarvinen, and P.T. Mannisto Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat J. Pharmacol. Exp. Ther. 304 2003 498 506
13. T. Funaki, H. Onodera, N. Ushiyama, Y. Tsukamoto, C. Tagami, H. Fukazawa, and I. Kuruma Lack of an effect of Madopar on the disposition of tolcapone and its 3-O-methylated metabolite in rats J. Pharm. Pharmacol. 47 1995 539 542
14. T. Funaki, H. Onodera, N. Ushiyama, Y. Tsukamoto, C. Tagami, H. Fukazawa, and I. Kuruma The disposition of the tolcapone 3-O-methylated metabolite is affected by the route of administration in rats J. Pharm. Pharmacol. 46 1994 571 574
15. N.H. Greig Drug delivery to the brain by blood-brain barrier circumvention and drug modification E.A. Neuwelt Implications of the Blood-Brain Barrier and Its Manipulation 1989 Plenum Publishing Corporation New York 311 368
16. H. Heikkinen, M. Saraheimo, S. Antila, P. Ottoila, and P.J. Pentikäinen Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man - a study using a stable isotope technique Eur. J. Clin. Pharmacol. 56 2001 821 826
17. M. Huotari, M. Santha, L.R. Lucas, M. Karayiorgou, J.A. Gogos, and P.T. Mannisto Effect of dopamine uptake inhibition on brain catecholamine levels and locomotion in catechol-O-methyltransferase-disrupted mice J. Pharmacol. Exp. Ther. 303 2002 1309 1316
18. M. Huotari, M. Passlin, H.L. Nordberg, M. Forsberg, S. Kotisaari, L. Tuomisto, F. Shintani, K.F. Tanaka, I. Reenila, L. Laitinen, and P.T. Mannisto Effect of intracerebral 6-nitronoradrenaline, an endogenous catechol-O- methyltransferase (COMT) inhibitor, on striatal dopamine metabolism in anaesthetised rats J. Neurosci. Methods 109 2001 47 52
19. K.M. Jorga, B. Fotteler, P. Heizmann, and G. Zürcher Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy Eur. J. Clin. Pharmacol. 54 1998 443 447
20. S. Kaakkola Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease Drugs 59 2000 1233 1250
21. S. Kaakkola, and R.J. Wurtman Effects of catechol-O-methyltransferase inhibitors and l-3,4-dihydrohyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum J. Neurochem. 60 1993 137 144
22. S. Kaakkola, and R.J. Wurtman Effects of COMT inhibitors on striatal dopamine metabolism: a microdialysis study Brain Res. 587 1992 241 249
23. T. Keränen, A. Gordin, M. Karlsson, K. Korpela, P.J. Pentikäinen, H. Rita, E. Schultz, L. Seppälä, and T. Wikberg Inhibition of soluble catechol-O-methyltransferase and single dose pharmacokinetics after oral and intravenous administration of entacapone Eur. J. Clin. Pharmacol. 46 1994 151 157
24. I. Kopin Catecholamine metabolism: basic aspects and clinical significance Pharmacol. Rev. 37 1985 333 364
25. D.A. Learmonth, M.A. Vieira-Coelho, J. Benes, P.C. Alves, N. Borges, A.P. Freitas, and P.S. da-Silva Synthesis of 1-(3,4-dihydroxy-5-nitrophenyl)-2- phenyl-ethanone and derivatives as potent and long-acting peripheral inhibitors of catechol-O-methyltransferase J. Med. Chem. 45 2002 685 695
26. I.-B. Lindén, E. Nissinen, E. Etemadzadeh, S. Kaakkola, P.T. Männistö, and P. Pohto Favorable effect of catechol-O- methyltransferase inhibition by OR-462 in experimental models of Parkinson's disease J. Pharmacol. Exp. Ther. 247 1988 289 293
27. T. Lotta, J. Vidgren, C. Tilgmann, I. Ulmanen, K. Melen, I. Julkunen, and J. Taskinen Kinetics of human soluble and membrane-bound catechol-O- methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme Biochemistry 34 1995 4202 4210
28. P.T. Männistö, and S. Kaakkola Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors Pharmacol. Rev. 51 1999 593 628
29. P.T. Männistö, M. Törnwall, P. Tuomainen, S.A. Borisenko, and R.K. Tuominen Effect of nitecapone and clorgyline, given intracerebroventricularly, on l-dopa metabolism in the rat brain Neuroreport 3 1992 641 644
30. A. Napolitano, G. Bellini, E. Borroni, G. Zurcher, and U. Bonuccelli Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats Parkinsonism Relat. Disord. 9 2003 145 150
31. A. Napolitano, G. Zürcher, and M. Da Prada Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of l-DOPA and dopamine in rats Eur. J. Pharmacol. 273 1995 215 221
32. E. Nissinen, I.B. Lindén, E. Schultz, and P. Pohto Biochemical and pharmacological properties of a peripherally acting catechol-O- methyltransferase inhibitor entacapone Naunyn Schmiedebergs Arch. Pharmacol. 346 1992 262 266
33. E. Nissinen, I.-B. Lindén, E. Schultz, S. Kaakkola, P.T. Männistö, and P. Pohto Inhibition of catechol-O-methyltransferase activity by two novel disubstituted catechols in the rat Eur. J. Pharmacol. 153 1988 263 269
34. W.M. Pardridge Transport of small molecules through the blood-brain barrier: biology and methodology Adv. Drug Deliv. Rev. 15 1995 5 36
35. G. Paxinos, and C. Watson The Rat Brain in Stereotaxic Coordinates first ed. 1982 Academic Press London
36. J. Savolainen, M. Forsberg, H. Taipale, P.T. Männistö, K. Järvinen, J. Gynther, P. Jarho, and T. Järvinen Effects of aqueous solubility and dissolution characteristics on oral bioavailability of entacapone Drug Dev. Res. 49 2000 238 244
37. J. Savolainen, J. Leppänen, M. Forsberg, H. Taipale, T. Nevalainen, J. Huuskonen, J. Gynther, P.T. Männistö, and T. Järvinen Synthesis and in vitro/in vivo evaluation of novel oral N-alkyl- and N,N-dialkyl-carbamate esters of entacapone Life Sci. 67 2000 205 216
38. B.H.C. Westerink, and J.B. De Vries A method to evaluate the diffusion rate of drugs from a microdialysis probe through brain tissue J. Neurosci. Methods 109 2001 53 58
39. G. Zürcher, J. Dingemanse, and M. Da Prada Ro 40-7592, a potent inhibitor of extracerebral and brain catechol-O-methyltransferase: preclinical and clinical findings A. Agnoli G. Campanella New Developments in Therapy of Parkinson's Disease 1991 John Libbey CIC s.r.l. Rome 37 43
40. G. Zürcher, H.H. Keller, R. Kettler, J. Borgulya, E.P. Bonetti, R. Eigenmann, and M. Da Prada Ro 40-7592, a novel, very potent, and orally active inhibitor of catechol-O-methyltransferase: a pharmacological study in rats Adv. Neurol. 53 1990 497 503